Stacey Knox, MD
Hematology & Oncology · Lincoln, NENPI 1750353447
Payments from drug & device makers
Across 194 payments — averaging $2954.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech, Inc.$221K
- Pharmacyclics LLC, An Abbvie Company$158K
- E.r. Squibb & Sons, L.L.C.$104K
- Bristol Myers Squibb$57K
- Merck$14K
- AstraZeneca$13K
- plus $6K from 21 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech, Inc. | 26 | $220,828 |
| Pharmacyclics LLC, An Abbvie Company | 61 | $158,069 |
| E.r. Squibb & Sons, L.L.C. | 26 | $103,744 |
| Bristol Myers Squibb | 14 | $56,760 |
| Merck | 9 | $13,938 |
| AstraZeneca(2 entities) | 9 | $13,428 |
| AbbVie | 8 | $5,211 |
| Astrazeneca UK Limited | 1 | $596 |
| Pfizer | 9 | $86 |
| Array Biopharma Inc | 4 | $83 |
| Daiichi Sankyo Inc. | 2 | $56 |
| EMD Serono, Inc. | 3 | $55 |
| CTI Biopharma Corp. | 3 | $48 |
| GSK | 3 | $45 |
| Novartis | 2 | $42 |
| AVEO Pharmaceuticals, Inc. | 1 | $40 |
| Eisai Inc. | 2 | $37 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $29 |
| Seagen Inc. | 1 | $23 |
| Verity Pharmaceuticals Inc. | 1 | $21 |
| Morphosys, US Inc. | 1 | $21 |
| Incyte Corporation | 1 | $19 |
| Agios Pharmaceuticals, Inc. | 1 | $18 |
| Exelixis Inc. | 1 | $15 |
| Adaptive Biotechnologies Corporation | 1 | $13 |
| Novocure Inc. | 1 | $13 |
| Gilead | 1 | $12 |
How this compares
$573,248 in reported general payments places this provider in the 65th percentile of 73 hematology & oncology providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in Lincoln
- Kailash MosalpuriaLincoln$4.2M
- Madhu MidathadaLincoln$1.1M
- Mark HutchinsLincoln$1.1M
- Eric AveryLincoln$1.1M
- Steven DunderLincoln$612K
- Alan BergLincoln$396K
- Joni TilfordLincoln$181K
- Nathan GreenLincoln$136K
- Scott McHamLincoln$33K
- Melissa CetakLincoln$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.